September 26, 2019
Teva Pharmaceutical Industries Ltd. will continue to face investors' proposed class claims that it misled them by telling them its revenue was increasing because of efficiency and good management while the company was fixing prices for generic drugs, a Connecticut federal judge ruled Wednesday.
January 14, 2019
Teva Pharmaceutical Industries Ltd. and its executives doubled down on their efforts to toss securities claims from investors, who say the drugmaker engaged in a price-hike scheme and misled them about its resulting profit growth, arguing in Connecticut federal court Friday they presented no evidence.
November 21, 2018
Investors suing Teva Pharmaceutical Industries Ltd. blasted a dismissal bid in Connecticut federal court by two former executives who claim that they did not sign the documents that allegedly concealed a price-hike scheme, saying that signature or no signature, the company officials were responsible for the content of the filings.
November 13, 2018
A proposed class of Teva Pharmaceutical Industries Ltd. shareholders urged a Connecticut federal court Monday to keep alive their allegations that the Israeli drugmaker falsely indicated that profit growth was driven by "fundamental business strategies" rather than at least 76 price hikes.
September 17, 2018
Teva Pharmaceutical Industries Ltd. has urged a Connecticut federal judge to let it escape a proposed class action accusing it of engaging in a price-hike scheme, saying it isn't unlawful to have a plan to increase product prices when the opportunity presents itself in the market.
April 04, 2018
A Connecticut federal judge on Tuesday dismissed a putative class action against Teva Pharmaceutical Industries Ltd. and several former officers from the bench, a suit in which investors claimed Teva hid a federal investigation into an alleged price-fixing scheme to inflate its stock price.
January 11, 2018
Two pension plans on Wednesday hit back against a request by Teva Pharmaceutical Industries Ltd. and several of its former officers to throw out their proposed investor class action over Teva's alleged price-fixing in the generic-drug market, defending the quality of their pleadings to a Connecticut federal court.
April 06, 2017
A California federal judge has consolidated two proposed class actions against Teva Pharmaceutical Industries Ltd. and several of its officers — both of which accuse Teva of misleading investors about an antitrust investigation by the U.S. Department of Justice — and moved the consolidated case to Connecticut federal court.